Considerations before choosing (extemporaneously) compounded products

Dermatologic Therapy

Volumn 22, Issue 3, 2009, Pages 225-228

  Krochmal, Lincoln ^a  

^a Excaliard Pharmaceuticals   (United States)

Author keywords

Extemporaneous compounding; Online sourcing; Recommendations; Risks

Indexed keywords

DECISION MAKING; DRUG SAFETY; ECONOMIC ASPECT; MEDICAL INFORMATION; MEDICOLEGAL ASPECT; PACKAGING; PHYSICIAN; PRESCRIPTION; REVIEW; SAFETY;

DERMATOLOGIC AGENTS; DERMATOLOGY; DRUG COMPOUNDING; HUMANS; RISK FACTORS; SKIN DISEASES;

EID: 65549115068     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/j.1529-8019.2009.01235.x     Document Type: Review

References (9)

1. Bouts B. The misuse of compounding by pharmacists. http://www.quackwatch. org/01QuackeryRelatedTopics/compounding.html. Accessed August 14, 2008.
2. Krochmal L, Patel B. Topical product design and extemporaneous compounding in dermatology. Adv Dermatol 1992 : 7 : 231 252 discussion 253.
3. Brown TR. Dermatologic prescriptions requiring compounding. J Am Acad Dermatol 1984 : 11 : 148 151.
4. Ling M. Extemporaneous compounding. Dermatol Ther 1998 : 16 (2 321 322.
5. Krochmal L, Wang JC, Patel B, Rodgers J. Topical corticosteroid compounding: effects on physicochemical stability and skin penetration rate. J Am Acad Dermatol 1989 : 21 (5 Pt 1 979 984. (Pubitemid 19268642)
6. Krochmal L. To compound or not? That is the question. Int J Dermatol 1991 : 30 (11 774.
7. Peck P. FDA cracks down on bio-identical hormones from compounding pharmacies. http://www.medpagetoday.com/ProductAlert/Prescriptions/tb/7908. Accessed August 14, 2008.
8. Thompson, et al. v Western States Medical Center, et al. US Supreme Court Case No. 01-344, decided April 29, 2002.
9. Heinrich J. Prescription drugs: state and federal oversight of drug compounding by pharmacies. GAO-04-195T, October 23, 2003.